Verastem, Inc. (VSTM)

Several events have impacted Verastem's stock price in the past six months. The FDA's accelerated approval of AVMAPKI FAKZYNJA CO-PACK was a positive catalyst. Despite exceeding analyst expectations with $11.2 million in net product revenue in Q3 2025, the stock dropped due to increased operating costs, a $26 million cash burn, and a high debt-to-equity ratio. Interim results from the RAMP 205 clinical trial led to a significant stock decline due to treatment-emergent serious adverse events, triggering an investigation. Insider selling has also occurred, contributing to stock volatility, with a 52-week range between approximately $3.45 and $11.24.

The demand for Verastem's products is primarily driven by disease prevalence, treatment efficacy, and regulatory approvals, rather than seasonal consumer patterns. There is no readily available information suggesting significant demand seasonality for Verastem's specialized pharmaceutical products.

Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing novel medicines for cancer treatment, particularly those addressing RAS/MAPK pathway-driven cancers. The company's pipeline includes drugs like Avutometinib, Defactinib, AVMAPKI FAKZYNJA CO-PACK (approved for KRAS-mutated recurrent low-grade serous ovarian cancer), and VS-7375. Verastem is involved in multiple clinical studies and has licensing and collaboration agreements with various companies.

Verastem, Inc. is headquartered in Needham, Massachusetts, United States, with operations primarily spanning the United States and Germany.

Verastem's brand reputation has been influenced by both positive and negative events. The FDA approval of AVMAPKI FAKZYNJA CO-PACK was a major positive, positioning the company as a leader in the LGSOC market. However, the disclosure of adverse events in the RAMP 205 clinical trial led to a stock price drop and an investigation, negatively impacting the company's reputation. The potential for toxicity issues associated with MEK inhibitors also poses a challenge.

Verastem, Inc. has a significant institutional ownership base, ranging from approximately 56.54% to 88.37%. Major institutional owners include Rtw Investments, Lp, Balyasny Asset Management Llc, Logos Global Management LP, Point72 Asset Management, L.P., BlackRock, Inc., Vanguard Group Inc, Stonepine Capital Management, LLC, Vivo Capital, LLC, Foresite Capital Management VI LLC and State Street Corp. Insider ownership ranges from approximately 1.08% to 2.10%, with retail investors and public companies holding the remaining shares.